DSCSA and EU FMD: An April 2026 Status Check on Pharmaceutical Serialisation and Verification

Where US DSCSA full enforcement and EU FMD operations stand at the start of Q2 2026 — and the recall and field-action implications for pharmaceutical manufacturers and supply chain participants.

The Two Frameworks in Early Q2 2026

For pharmaceutical manufacturers, distributors, and dispensers operating across the United States and the European Union, the operational landscape for product traceability and verification is materially more mature in 2026 than it was even two years ago. Two regulatory frameworks anchor that landscape.

The US Drug Supply Chain Security Act (DSCSA), enacted in 2013, established a phased path to interoperable, electronic, package-level traceability across the US pharmaceutical supply chain. Following the FDA's stabilisation period — during which enforcement discretion was exercised to allow trading partners to complete the operational and technical work needed for full electronic traceability — full enforcement is now in effect for most categories of trading partners. The operational picture is one of EPCIS-based serialised data exchange, structured trading-partner relationships, and verification-on-demand for suspect product investigation.

The EU Falsified Medicines Directive (FMD) — Directive 2011/62/EU, supported by the Delegated Regulation (EU) 2016/161 — has been operationally live across the EU and EEA since February 2019, with the European Medicines Verification System (EMVS) providing the technical infrastructure. The framework requires manufacturers to apply unique identifiers and tamper-evident packaging to most prescription medicines and requires dispensers to verify and decommission those identifiers at the point of dispense.

Both frameworks were originally framed primarily around supply chain security — preventing falsified medicines from reaching patients — but their operational data has, predictably, become useful for a much broader set of quality, traceability, and recall purposes.

DSCSA in Early 2026: From Enforcement Stabilisation to Operational Reality

The DSCSA stabilisation period, which extended into 2025, was used by FDA to acknowledge the practical difficulty of bringing the full US pharmaceutical supply chain into interoperable electronic traceability. By the start of Q2 2026, the stabilisation period has lapsed for most categories of trading partners, and FDA's posture has shifted from "supporting readiness" to "enforcing operational compliance."

For pharmaceutical manufacturers, this shift has three immediate operational implications.

First, the data quality bar has risen materially. During the stabilisation period, trading partners exchanged EPCIS data with varying levels of completeness, accuracy, and timeliness. With enforcement in force, the standard is interoperable data exchange that allows downstream trading partners to perform the verification, suspect-product investigation, and saleable-returns processing the law contemplates. Manufacturers whose EPCIS messages have weak data quality are now likely to receive trading-partner exception reports and FDA inquiries.

Second, the verification-on-demand capability is now expected to function in production. When a downstream trading partner or FDA initiates a verification request — for a suspect product investigation, a saleable returns processing event, or a routine integrity check — the manufacturer is expected to respond inside the documented service level. Manufacturers whose verification systems are operationally unstable, or who have not adequately staffed the function, are exposed.

Third, the integration of DSCSA data into recall and field-action processes is now operationally important. The unique identifier infrastructure that DSCSA establishes makes it possible to execute recalls with much greater precision than was historically achievable in the US pharmaceutical supply chain — at the level of specific serialised packages or specific lots within distributor inventory, rather than the broad category of "all units of NDC X manufactured between dates Y and Z." Manufacturers that have integrated their DSCSA infrastructure with their recall and field-action processes are in a materially stronger position to execute precise recalls than those that have not.

EU FMD in Early 2026: Operational Maturity, Continuing Enhancement

The EU FMD framework has been operationally live for over seven years as of early 2026. The European Medicines Verification System (EMVS) and the connected national medicines verification systems are mature operational infrastructure, with millions of verification and decommissioning events per day across the EU and EEA.

The 2026 picture for EU FMD is therefore not about implementation but about ongoing enhancement and the integration of FMD operational data into adjacent quality and recall processes.

The most material operational topic in 2026 is the continuing work on alert management. The EMVS generates alerts when verification or decommissioning events do not match the manufacturer-supplied data — for example, when a dispenser attempts to decommission a unique identifier that has already been decommissioned, or when a serial number is presented that the manufacturer's data does not recognise. Each alert is a potential signal of falsification, of a data quality issue, of an operational error, or of a process inconsistency. The alert volume is non-trivial, and the discipline of working through alerts to identify and act on the small share that represent genuine safety or supply chain integrity issues is now a steady-state operational function.

The second material topic is the integration of FMD data with recall and field-action processes. As with DSCSA, the unique identifier infrastructure makes it possible to execute pharmaceutical recalls in the EU with much greater precision than was historically achievable. Manufacturers who have built the integration between their recall management process and their FMD infrastructure can rapidly identify which serialised packages of a recalled product have been verified at which dispenser locations, supporting precise communication and follow-through with the affected trading partners.

The third material topic is the relationship between FMD data and the post-market surveillance obligations under the EU MDR (for medical devices) and the EU regulatory frameworks for pharmaceuticals. The data lives in the FMD systems for purposes specified by the directive; using it for adjacent post-market surveillance purposes requires careful attention to the data protection and purpose-limitation framework that governs its use.

Where DSCSA and EU FMD Differ — and Why It Matters for Recalls

For multinational pharmaceutical manufacturers, a clear understanding of where DSCSA and EU FMD differ is necessary for operating recall processes that span both jurisdictions.

The frameworks share a common technical foundation — unique identifiers at the package level, tamper-evident packaging, electronic data exchange, verification by trading partners — but they differ in important operational details.

• DSCSA is built around the trading-partner network: manufacturers, repackagers, wholesale distributors, and dispensers exchange EPCIS-based traceability data, with FDA in the role of inspectorate and ultimate consumer of traceability data on demand. Verification and decommissioning are not centralised in the way they are under FMD.
• EU FMD is built around the centralised verification system (EMVS) and the national medicines verification systems, with manufacturers uploading data and dispensers performing verification and decommissioning against the national systems. The architecture is materially more centralised than DSCSA.
• The scope of products covered differs: DSCSA applies to most prescription drugs in finished dosage form, with category-specific scope decisions; FMD applies to most prescription medicines (with a narrower set of exceptions than the historical US scope).
• The recall-relevant data picture differs: DSCSA's transaction data shows the chain of custody from manufacturer to dispenser; FMD's verification data shows the dispense events at the point of patient supply. Each is useful for recall execution; the combination is useful for multinational operations.

For multinational manufacturers operating recalls across both regions, the practical pattern is to maintain a recall execution playbook that draws on the appropriate data source in each jurisdiction — DSCSA transaction data in the US, EMVS verification data in the EU — through a single recall management workflow.

The Recall Execution Implications

The combined effect of mature DSCSA and EU FMD infrastructure on pharmaceutical recall execution in 2026 is significant. Manufacturers with mature integrations between their recall processes and the relevant traceability infrastructure can:

• Identify the precise scope of affected product in the supply chain at the level of serial number, lot, and trading partner — rather than relying on broader category-level scoping.
• Execute precise trading-partner notification with information that allows recipients to identify the specific units in their inventory affected by the recall, supporting more efficient retrieval.
• Verify the effectiveness of recall execution against actual decommissioning data (in the EU) and saleable returns data (in the US), rather than relying on self-reported retrieval data from trading partners.
• Provide regulators with precise execution data during recall reviews and post-recall reporting, supporting faster file closure.

Manufacturers without these integrations execute recalls in the older mode — broader scope, less precise notification, less efficient retrieval, and post-recall reporting that depends on aggregated trading-partner reports rather than infrastructure-derived data. The cost of the older mode in operational, financial, and reputational terms is increasingly visible.

An Early-Q2 Readiness Checklist

For pharmaceutical manufacturers operating across both frameworks, a focused readiness checklist for the months ahead:

• [ ] DSCSA EPCIS data quality — review error rates against trading partners' acceptance feedback; close systematic data quality issues.
• [ ] DSCSA verification-on-demand operations — confirm staffing, service-level performance, and escalation procedures for production verification requests.
• [ ] EMVS alert management — review alert volume, classification, and resolution time-to-close; confirm that alert management is integrated with internal quality and security processes.
• [ ] Recall integration — verify that the recall management workflow can draw on DSCSA transaction data (US) and EMVS verification data (EU) for affected-product identification and trading-partner notification.
• [ ] Multinational recall coordination — confirm that the recall playbook handles the differences between DSCSA and EMVS data and execution patterns without losing the audit trail.
• [ ] Cross-functional ownership — confirm that supply chain integrity, quality, regulatory affairs, and recall response leaders are operating against a common picture of the framework's status and the manufacturer's posture.

How Software Helps

Recall management software's role in this picture is specific. The serialisation and verification infrastructure itself — EPCIS data exchange, EMVS interfaces, manufacturer master data management — typically lives in dedicated supply chain integrity systems. The recall management platform provides the workflow layer above those systems where recall and field-action execution happens, where the audit trail is held, and where regulator interactions are documented.

SuperRecall.ai monitors 44+ regulatory databases including FDA recall and enforcement reports, EMA centralised actions, member-state pharmaceutical regulator alerts, EMVS-related EU communications, and complementary feeds across other major markets. Its workflow supports structured incident management with role-based access control and a tamper-evident audit log. For pharmaceutical manufacturers building toward a recall execution capability that takes full advantage of mature DSCSA and FMD infrastructure, the platform is designed to operate as the system of record for the recall workflow itself, integrating with the supply chain integrity systems where the underlying serialisation data lives. SuperRecall.ai's SOC 2 posture is currently Audit In Progress, and we are happy to discuss the current state with security and procurement teams that need to verify the picture.

Closing Note

DSCSA and EU FMD have moved from "framework being implemented" to "framework being operated." The practical question for pharmaceutical manufacturers in 2026 is no longer compliance with the implementation timeline but operational maturity in the use of the framework's data — for supply chain security, for verification, and increasingly for precise recall execution.

If your team would like to walk through how SuperRecall.ai supports recall and field-action execution in mature DSCSA and FMD environments, book a working session or contact sales@superrecall.ai. Our pharmaceutical recall management guide and the preventing Class I drug recalls playbook are useful companion reading.